BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9479010)

  • 1. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
    Gromada J; Holst JJ; Rorsman P
    Pflugers Arch; 1998 Apr; 435(5):583-94. PubMed ID: 9479010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
    Gromada J; Brock B; Schmitz O; Rorsman P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
    Gromada J; Rorsman P
    Horm Metab Res; 2004; 36(11-12):822-9. PubMed ID: 15655714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
    Thorens B; Waeber G
    Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.
    Holz GG
    Horm Metab Res; 2004; 36(11-12):787-94. PubMed ID: 15655710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
    Ahrén B
    Bioessays; 1998 Aug; 20(8):642-51. PubMed ID: 9780839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37).
    Holz GG; Leech CA; Heller RS; Castonguay M; Habener JF
    J Biol Chem; 1999 May; 274(20):14147-56. PubMed ID: 10318832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 10. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
    Gromada J; Ding WG; Barg S; Renström E; Rorsman P
    Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The recombinant rat glucagon-like peptide-1 receptor, expressed in an alpha-cell line, is coupled to adenylyl cyclase activation and intracellular calcium release.
    Dillon JS; Lu M; Bowen S; Homan LL
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):182-9. PubMed ID: 15789279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
    Drucker DJ
    Mol Endocrinol; 2003 Feb; 17(2):161-71. PubMed ID: 12554744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
    Byrne MM; Göke B
    Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transduction of PACAP and GLP-1 in pancreatic beta cells.
    Leech CA; Holz GG; Habener JF
    Ann N Y Acad Sci; 1996 Dec; 805():81-92; discussion 92-3. PubMed ID: 8993395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin.
    Fehmann HC; Göke R; Göke B
    Mol Cell Endocrinol; 1992 May; 85(1-2):C39-44. PubMed ID: 1382025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 in NIDDM.
    Holst JJ
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity.
    Yada T; Itoh K; Nakata M
    Endocrinology; 1993 Oct; 133(4):1685-92. PubMed ID: 8404610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.